A Genotype Associated with Diminished Response to Clopidogrel

A genomewide association study nudges genetic testing closer to clinical practice.

Clopidogrel improves outcomes in most patients with acute coronary syndromes, but poor responsiveness to clopidogrel is common and is associated with recurrent ischemic events. In the Pharmacogenomics of Antiplatelet Intervention (PAPI) Study, researchers measured platelet aggregation in 429 Amish adults who had taken clopidogrel for 7 days. The investigators performed a genomewide association study and genotyped the loss-of-function cytochrome P450 (CYP) 2C19*2 variant. They tested their findings and assessed the variant's relation to cardiovascular events in an independent U.S. population sample of 227 individuals undergoing percutaneous coronary intervention.

In the PAPI participants, platelet responsiveness to clopidogrel was highly heri…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)